Table 1 The clinical and pathological features of patients
Variables Median (range) or n (%) | Total n = 103 | Prostate cancer n = 53 | No prostate cancer n = 50 | P |
|---|---|---|---|---|
Age, years | 69 (37–83) | 71 (48–79) | 67 (37–83) | <0.01† |
No. of TRUS biopsies | 1 (1–5) | 1 (1–5) | 1 (1–3) | 0.48† |
No. of cores obtained pre-TRUSBs | 12 (8–13) | 12 (8–13) | 12 (8–12) | 0.89† |
PSA, ng/mL | 9.2 (1.9–107) | 10.7 (1.9–42.1) | 8.8 (4.5–107) | 0.33† |
Free-PSA ratio, % | 15.3 (1.3–67.1) | 12.9 (4.3–25.7) | 16.9 (1.3–67.1) | 0.04† |
PSA density, ng/mL/mL | 0.26 (0.06–1.9) | 0.33 (0.06–1.3) | 0.23 (0.07–1.9) | 0.02† |
PSA velocity, ng/mL/year | 1.12 (−29–129) | 1.39 (−29–26) | 0.75 (−8.8–129) | 0.66 |
DRE, abnormal findings | 17 (16.5) | 13 (24.5) | 4 (8.0) | 0.03‡ |
TRUS, abnormal findings | 21 (20.3) | 14 (26.4) | 7 (14.0) | 0.13‡ |
MRI, abnormal findings (n = 14) | 9/14 (64.2) | 6/9 (66.7) | 3/5 (60.0) | 0.93‡ |
Prostate volume, mL | 34.7 (18–76.7) | 30.8 (18–65.1) | 39.4 (20.1–76.7) | <0.01† |
HGPIN on previous biopsy | 13 (12.6) | 7 (13.2) | 6 (12.0) | 0.88‡ |
ASAP on previous biopsy | 10 (9.7) | 8 (15.1) | 2 (4.0) | 0.06‡ |
No of cores obtained by TTSB | 37 (18–75) | 32 (22–66) | 41.5 (18–75) | <0.01† |
Core/volume, cores/mL | 1.05 (0.80–1.77) | 1.05 (0.80–1.31) | 1.05 (0.80–1.77) | 0.07† |